We recently demonstrated that the mammalian target of rapamycin (mTOR) inhibitor, CCI-779, curtailed the growth of a subcutaneous challenge of multiple myeloma (MM) cells in immunodeficient mice. This antitumor effect was associated with prevention of cell proliferation, induction of apoptosis and inhibition of angiogenesis. Interestingly, myeloma tumors with heightened AKT activation were particularly sensitive to a CCI-779-induced antitumor response. To investigate whether part of the differential sensitivity was due to an AKT-regulated effect on angiogenesis, we compared the effects of mTOR inhibitors against isogenic MM cell lines that only differ by their degree of AKT activity. In this model, heightened AKT activity significantly sensitized MM cells to the following inhibitory effects of mTOR inhibition: angiogenesis in vivo, vascular endothelial growth factor (VEGF) expression in vitro and in vivo and VEGF translation (but not transcription). Assessment of p70S6 kinase activity indicated that rapamycin induced comparable mTOR inhibition in both cell lines suggesting that an adverse effect on VEGF cap-dependent translation would be comparable. Internal ribosome entry site (IRES)-mediated cap-independent translation is a salvage pathway for protein expression when mTOR is inhibited, so we analyzed a possible regulatory role of AKT on VEGF IRES activity. We found that elevated AKT activity inhibited VEGF IRES function. These results support a mechanism whereby AKT prevents VEGF IRES activity in myeloma cells during mTOR inhibition resulting in a more complete abrogation of VEGF translation, and ultimately, angiogenesis.
Introduction
Mammalian target of rapamycin (mTOR) inhibitors have demonstrated potential in preclinical studies as effective agents against multiple myeloma (MM) (Tu et al., 2000; Hideshima et al., 2001; Hsu et al., 2001) . In a xenograft model, we showed that the mTOR inhibitor, CCI-779, was an effective anti-myeloma drug, inhibiting in vivo tumor growth of OPM-2, 8226 and U266 MM tumors (Frost et al., 2004; Yan et al., 2006) . Interestingly, the level of AKT activity was correlated with antitumor response to CCI-779, with OPM-2, which expresses constitutively active AKT owing to a phosphatase and tensin homolog deleted on chromosome ten (PTEN) mutation (Hyun et al., 2000) , being the most sensitive. Confirmation of a true regulatory effect of AKT on sensitivity was obtained when an activated AKT allele was stably transfected into U266 cells. This stably transfected myeloma line was considerably more sensitive in vivo to the antitumor effects of mTOR inhibition than its empty vector transfected control (Frost et al., 2004; Yan et al., 2006) .
One of the AKT-dependent antitumor effects that we identified was associated with an inhibition of angiogenesis (Frost et al., 2004) . Recent work has underscored the importance of angiogenesis in progression of myeloma. The degree of angiogenesis inversely correlates with patient survival in disseminated myeloma (Rajkumar et al., 2000) as well as in solitary plasmacytomas of bone (Kumar et al., 2003) . Furthermore, microvessel density (MVD) decreases significantly in MM patients responding to certain therapies but not in non-responders (Kumar et al., 2004) . In myeloma, angiogenesis may be critical for the migration of tumor cells and their subsequent spread throughout the skeleton. In addition, cytokines which promote angiogenesis and are expressed at high levels in myeloma bone marrow also support myeloma cell growth and viability (Dankbar et al., 2000) . These angiogenic cytokines overexpressed in myeloma include vascular endothelial growth factor (VEGF) (Bellamy et al., 1999) , basic fibroblast growth factor (Chesi et al., 1997) and hepatocyte growth factor (HGF) (Sezer et al., 2001) .
As the ability of CCI-779 to induce an anti-myeloma response in vivo was so dependent on AKT activity, we initiated the current study investigating whether the observed antiangiogenic effect was likewise regulated by AKT. Our results confirm an AKT-dependent regulation of the antiangiogenic effect and, furthermore, point to a regulation of VEGF internal ribosome entry site (IRES)-mediated translation as an explanation.
Results
The CCI-779 mTOR inhibitor prevents tumor angiogenesis in an AKT-dependent manner CCI-779 treatment of immunodeficient mice challenged with OPM-2 or 8226 MM cell lines results in tumor regression associated with inhibition of proliferation and angiogenesis, and the induction of apoptosis (Frost et al., 2004) . Our initial studies using the U266 cell line transfected with an activated AKT allele indicated that heightened AKT activity sensitizes to the CCI-779 antitumor response in vivo. To test whether AKT activity specifically regulates an antiangiogenic effect, we used the same model.
Mice were challenged with U266 cells stably expressing a constitutively activated AKT allele (U266 AKT ) or the empty-vector control (U266 EV ). The cells were injected subcutaneously and, when the tumors reached 200-400 mm 3 , the mice were randomized into groups to receive increasing doses of CCI-779 (five daily injections, then 2 days rest, and an additional five daily injections) or vehicle alone. Tumors were excised on day þ 13 (24 h after the last injection of CCI-779) and processed for immunohistochemical analysis of MVD by in situ staining with anti-CD34 antibody. Figure 1a shows a quantitative assessment of the antiangiogenic effect of CCI-779 on MVD that was approximately fivefold greater in the AKT-transfected tumors compared to the EV controls (P>0.05). The ID 50 for CCI-779's effect on MVD was B5 mg/kg in these tumors as compared to over 20 mg/kg in the control tumors. Figure 1b shows representative sections of CD34-stained tumors demonstrating the effects of 20 mg/kg CCI-779 on angiogenesis.
Identification of VEGF as the likely angiogenic factor decreased by mTOR inhibitors and regulated by AKT Angiogenesis is a complex phenomenon regulated by several different cytokines. As mTOR inhibitors have a known inhibitory effect on expression of certain proteins, we hypothesized that the depression of MVD achieved by these drugs was due to adverse effects on angiogenic cytokine expression. To identify which of these cytokines may be downregulated by mTOR inhibitors in an AKT-dependent manner, we screened for the expression of angiogenic factors using an angiogenesis antibody array (Panomics) in U266 isogenic cells treated with rapamycin in vitro. Rapamycin is equipotent on a molar basis to CCI-779 in its ability to inhibit mTOR activity. This array allowed us to screen cell lysate for the expression of 19 angiogenic cytokines (angiogenin, fibroblast growth factor (FGF)a, FGFb, granulocyte colony-stimulating factor (G-CSF), HGF, interleukin (IL)-1a, IL-1b, IL-6, IL-8, IL-12, interferong, interferon-producing protein 10, leptin, PIGF, tissue inhibitors of metalloproteinases (TIMP)-1, TIMP-2, transforming growth factor a, tumor necrosis factor a and VEGF) in both isogenic U266 cell lines treated for 48 h with 10 nM of rapamycin. Of these 19 angiogenic factors, only seven (FGFa, FGFb, HGF, IL-8, IL-12, TIMP-2 and VEGF) were consistently expressed in U266 (representative experiment shown in Figure 2 ). In the basal state (no rapamycin), there was little difference in expression of the panel of angiogenic factors observed between the two isogenic cell lines. The one exception was the tissue inhibitors of metalloproteinases-2 (TIMP-2), whose expression was downregulated in the U266 AKT cells. Of these seven angiogenic factors, only IL-8 (Figure 2 , solid box) and VEGF (Figure 2 , dotted box) appeared to be downregulated by rapamycin in the screening assay. In the experiment shown, rapamycin appeared to downregulate the expression of IL-8 in both isogenic lines equally. IL-8 (and to a lesser extent, HGF) was inconsistently inhibited by rapamycin. In some To confirm the above results, a full dose-response experiment for VEGF expression was performed on the isogenic U266 cell lines exposed to rapamycin in vitro and on U266 tumors harvested from mice that had been treated with CCI-779 in vivo. As shown in Figure 3a , there was a dose-dependent decrease in VEGF secretion in U266 AKT cells exposed to rapamycin which was significantly greater then the modest response induced in U266 EV cells. The ID 50 was o0.1 nM for the 'high AKT' MM cells, while 50% inhibition was not reached at any dose in U266 EV cells. We also tested the VEGF expression in vivo on tumor cell lysate after 13 days of CCI-779 treatment ( Figure 3b ). VEGF expression was normalized to protein concentrations (mg protein/ml lysate) in these tumors. As shown in Figure 3b , treatment with CCI-779 induced a dose-dependent decrease in VEGF expression, which was significantly greater in U266 AKT tumors. The ID 50 for these tumors was approximately 5 mg/kg, while 50% inhibition of VEGF expression in U266 EV tumors was not reached at any dose of CCI-779 tested. These data closely mirror the effects of CCI-779 on MVD in these same tumors shown above ( Figure 1 ). As the screening assay raised questions about the role of IL-8 (and to a lesser extent HGF), we also performed ELISA experiments that confirmed that rapamycin inhibited IL-8 and HGF expression but this effect was comparable in both cell lines (i.e. not AKT-dependent) (data not shown).
Additional experiments suggest that AKT can regulate the VEGF response to mTOR inhibitors in MM cell lines where AKT is upregulated by non-artificial means (i.e. not by transfection). Of several myeloma cell lines tested, the OPM-2 line, which expresses heightened AKT activity owing to PTEN mutation (Hyun et al., 2000) , was the most sensitive to mTOR inhibitors in their ability to suppress VEGF expression. The ID 50 for rapamycin's effect on VEGF expression in OPM-2 cells (1 nM) was approximately 100 Â fold lower than that of MM cell lines with wild-type PTEN and quiescent AKT. The expression of VEGF in tumor lysate of OPM-2 tumors was also markedly more sensitive to CCI-779, with an ID 50 of B5 mg/kg, while 50% inhibition of VEGF expression in MM tumors with wild-type PTEN was not reached even at the highest dose tested (20 mg/ kg). These data are also consistent with our previous report that PTEN-mutated OPM-2 tumors are significantly more sensitive than PTEN wild-type tumors to the antiangiogenic effects of CCI-779 in vivo (Frost et al., 2004) .
Effects on RNA expression of VEGF VEGF expression is regulated post-transcriptionally by alternative mRNA splicing with at least six isoforms of VEGF ranging in size from 121 to 206 amino acids. Most cells, including MM, express VEGF 121 and VEGF 165 , with relatively little amounts of the other isoforms (Bellamy et al., 1999 ). Thus, we tested whether rapamycin or AKT activity could result in alterations in RNA splicing by utilizing polymerase chain reaction (PCR) primers that allow for the characterization of VEGF transcripts based on their size (Podar et al., 2001) . Figure 4a shows that U266 isogenic cell lines express the VEGF 121 and VEGF 165 RNA isoforms, which is consistent with other reports of myeloma cells (Bellamy et al., 1999; Dankbar et al., 2000; Podar et al., 2001) . There was no change in the expression patterns of the VEGF isoforms in U266 isogenic cell lines treated with or without rapamycin (10 nM).
The results of the above reverse transcriptase (RT)-PCR experiment also suggest that rapamycin and AKT activity had no effect on steady state levels of VEGF RNA. To further investigate this question, Northern blot analysis was performed. As shown in Figure 4b , relative amounts of VEGF mRNA were comparable in both 'high-AKT' and 'low-AKT' U266 cells (Figure 4b ). In addition, the levels of VEGF mRNA were not significantly affected by 48-h treatment with 10 nM rapamycin, a concentration that markedly inhibited VEGF expression (Figure 3a above) .
Downregulation of VEGF expression in AKT-transfected MM cells is due to effects on translational efficiency
As there were no significant effects of rapamycin on VEGF RNA levels, we next turned to potential effects on translational efficiency. An assessment of p70S6 kinase activity indicated that rapamycin induced comparable mTOR inhibition in both cell lines (data not shown) suggesting that adverse effect on cap-dependent translation would be comparable. To address whether heightened AKT activity regulated the ability of mTOR inhibitors to inhibit translation of VEGF, we used the ribosomal loading assay described by Zong et al. (1999) . This assay is based on the fact that actively translated mRNA species are associated with multiple ribosomes (polysomes), whereas poorly translated mRNAs are associated with single ribosomes (monosomes) (Zong et al., 1999) . Following separation of polysomes from monosomes (by sucrose gradient), the translational state of a specific transcript can then be estimated by the ratio of polysome-associated RNA to monosome-associated RNA (measured by Northern blot analysis). The U266 isogenic cell lines were treated with or without 10 nM rapamycin for 48 h and the cellular extracts were separated by sucrose gradient centrifugation and fractionated into 11 1-ml fractions . The ultraviolet (UV) absorbance (254 nm) of each fraction was measured to generate a polysome profile of the sucrose gradient that was used to differentiate between the monosome (fractions 1-3) and polysome (fractions 4-11) fractions.
The Northern blot analysis of VEGF or control actin on RNA isolated from the corresponding monosome and polysome fractions is shown in Figure 5 . The relative amounts of VEGF mRNA in polysome versus monosome fractions were determined by densitometric analysis of equally exposed autoradiographs and the percent polysomal RNA is shown to the right of each Northern blot. As can be seen, rapamycin (RAPA) at 10 nM was very effective in inhibiting translational efficiency of VEGF in U266 AKT cells (right panel), decreasing the percent of VEGF mRNA associated with the polysomal fractions from 40 to 8.5%. As expected, rapamycin also inhibited translational efficiency of the actin RNA in these cells (decrease from 60 to 26%). In contrast, the U266 EV cells (left panel) were relatively resistant to rapamycin in terms of inhibition of VEGF translation (actually slightly increasing the translational efficiency from 60 to 68%). However, the drug was still able to significantly inhibit actin translation in this latter cell line (from 72 to 50% as shown). Thus, mTOR effects on translational efficiency of VEGF are AKT-dependent, whereas those on actin translation are not. This experiment was repeated once with similar results.
Heightened AKT activity inhibits cap-independent translation mediated by the VEGF IRES The default 'cap-dependent' mechanism of translation depends on eIF-4E in the initiation complex binding to the cap structure at the 5 0 end of mRNA, thus Figure 4 Effects of AKT activity on VEGF mRNA in rapamycintreated U266 MM cells. (a) Isogenic U266 cell lines were treated with or without 10 nM rapamycin for 48 h and then RT-PCR analysis for VEGF splice variants was performed. The VEGF splice variants, VEGF 121 and VEGF 165 were expressed equally in both U266EV and U266AKT cells, and rapamycin treatment had no effect. (b) Northern blot analysis of VEGF transcripts in isogenic U266 cell lines treated with or without 10 nM rapamycin for 48 h. Total cellular RNA (5 mg) was electrophoresed on a denaturing formaldehyde agarose gel and transferred to a nylon membrane. The membrane was then probed with a 32P-labeled riboprobe specific for VEGF or GAPDH.
Angiogenesis, mTOR and multiple myeloma P Frost et al promoting ribosome recruitment to the transcript (Raught and Gingras, 1999) . However, a 'salvage' cap-independent mechanism exists, whereby IRESsequences located in the 5 0 -UTR (untranslated region) of VEGF mRNAs allow for translation by recruiting the small 40S ribosomal subunit to the mRNA and initiating translation under conditions in which cap-dependent protein translation may be inhibited (Huez et al., 1998; Miller et al., 1998) . Thus, one possible explanation for AKT-dependent regulation of translational efficiency is that AKT regulates the ability of VEGF to be translated by cap-independent mechanisms. In this scenario, mTOR inhibition results in diminished cap-dependent translation, whereas VEGF IRES sequences regulate cap-independent protein translation in an AKT-dependent manner. A functional IRES has been previously identified in the VEGF mRNA (Akiri et al., 1998; Huez et al., 1998; Miller et al., 1998) .
To test the above hypothesis, we utilized a dicistronic reporter assay where the VEGF 5 0 -UTR is subcloned into the intracistronic space between Renilla and firefly luciferase cistrons. As a recent study demonstrated that much of the downstream firefly luciferase expression results from cryptic promoter activity in the VEGF 5 0 -UTR, we used the strategy of Bert et al. (2006) , exploiting RNA transfection using dicistronic RNAs to avoid this cryptic promoter activity. To achieve this, the control (pRF) dicistronic reporter construct or the corresponding construct containing the VEGF 5 0 -UTR in the dicistronic space (pR-VEGF-F) were inserted into the pSP65-20B vector, which contains the SP6 RNA polymerase promoter and an encoded 38 nucleotide poly(A) tail (a gift from Dr Greg Goodall). Polyadenylated dicistronic mRNAs were generated in vitro (Figure 6a ) and transfected into isogenic U266 cells. The Renilla and firefly luciferase activity was then measured and the relative luciferase activity of Figure 5 Polysome analysis of VEGF mRNA in isogenic U266 MM cell lines. Isogenic U266 cells were treated with and without 10 nM rapamycin for 48 h and polysomes were separated from monosomes by sucrose gradients. Northern blots were performed on the gradient fractions for VEGF (a) and actin (b) mRNAs. The percent of total mRNA present (measured by densitometry of equally exposed Autoradiographs) in the polysomal fractions (fractions 4-11) are shown to the right of the autoradiographs. This experiment was performed one additional time with identical results. Angiogenesis, mTOR and multiple myeloma P Frost et al pR-VEGF-F RNA compared to the pRF control RNA was determined in cells treated with and without rapamycin.
As shown in Figure 6b , transfection of U266 EV cells (left panel) with RNA containing the VEGF 5 0 -UTR in the intra-cistronic region resulted in a 10-12-fold increase in relative firefly luciferase activity compared to transfection with the control pRF mRNA. In contrast, the relative firefly luciferase activity in U266 AKT cells (right panel) was only 2-3-fold over the control mRNA, indicating that heightened AKT activity inhibited the cap-independent translation of the firefly cistron mediated by the VEGF IRES. Importantly, the Renilla luciferase activity was similar for both cell lines, indicating that cap-dependent translational mechanisms were independent of AKT activity. Interestingly, rapamycin treatment (100 nM for 24 h) significantly increased VEGF IRES activity in the U266 EV cells (left panel) but this effect was prevented in the U266 AKT cells (right panel). Thus, AKT negatively regulates VEGF IRES activity in untreated cells and prevents any further increase in IRES activity occurring following mTOR inhibition.
Discussion
The results of this study indicate that heightened AKT activity sensitizes MM cells to the antiangiogenic effects of mTOR inhibitors. Furthermore, the data suggest that AKT's regulatory effect is due to an influence on VEGF expression. Steady state levels of VEGF mRNA were not affected by rapamycin but the inhibited protein expression was associated with a decrease in translational efficiency of VEGF transcripts and this latter effect was likewise regulated by AKT activity. Although we did not assess possible differential effects on VEGF protein stability which could have played a role in our results, it seems probable that the differential effect of mTOR inhibitors on VEGF expression is a least partly due to AKT's effect on the translational response to these drugs.
Under most conditions, cap-dependent protein translation is the default mechanism for protein translation (Bjornsti and Houghton, 2004) . However, an alternative, IRES-regulated salvage pathway allows for RNA translation under conditions in which cap-dependent protein translation is inhibited, such as during exposure to rapamycin. In recent work in other tumor models, AKT activity has been shown to negatively regulate the IRES function of c-myc and cyclin D1 Shi et al., 2005) . We now describe a third IRES, that of VEGF, whose function is also regulated by AKT activity. As all three 5 0 -UTRs contain IRESes that are regulated by AKT, it is likely that an identical mechanism of AKT regulation is operative among these different RNAs.
IRES-trans activating factors (ITAFs) are proteins critical for IRES function. These factors bind to RNA at specific sites in the 5 0 -UTR and induce conformational changes that facilitate recruitment of the ribosome to the IRES (Stoneley et al., 2000; Evans et al., 2003) . Thus, one possible explanation for AKT's regulatory role is that it affects expression or binding of specific ITAFs to the VEGF IRES. AKT may influence these ITAF activities directly or indirectly. A possible example of an indirect influence is the inhibitory effect of AKT on p38 and extracellular signal-regulated protein kinase (ERK) mitogen-activated protein kinase function (Berra et al., 1998) . These kinases are important for myc IRES function (Shi et al., 2005) , and the ability of AKT to downregulate their activity explains AKT's negative regulatory role. Experiments are underway to determine if p38 and/or ERK are also important for VEGF IRES function.
Regulation of VEGF expression is complex. Under hypoxic conditions, upregulation of VEGF is mediated by the hypoxia-induced factor-1 (HIF-1), which induces VEGF transcription. The activity of HIF-1 is primarily regulated by rapid (o5 min) degradation of the a-subunit via the ubiquitin/proteosome pathway during normal oxygen conditions (Huang et al., 1996) . However, under hypoxic conditions, HIF-1a degradation is inhibited, thereby resulting in an increase in the level of HIF-1a protein and the subsequent upregulation of VEGF transcription (Shweiki et al., 1992) . In other tumor models, mTOR inhibitors downregulate angiogenesis by inhibiting HIF-1 expression that was not due to affects on HIF protein stability (Laughner et al., 2001) . In contrast, in our myeloma model, there were no effects of mTOR inhibitors on VEGF mRNA levels under normoxic conditions, indicating that alterations in HIF-1 did not play a role in the depressed VEGF protein levels. It will be interesting to see if AKT also plays a similar role in regulating VEGF IRES function under hypoxic conditions as well.
In this study, we focused on AKT-dependent effects on angiogenesis and VEGF expression in rapamycin/ CCI-779-treated MM cells. However, our prior study on use of CCI-779 in vivo against myeloma xenografts, indicated additional effects on apoptosis that correlated with the inhibition of angiogenesis (Frost et al., 2004) . In preliminary experiments with our U266 isogenic cell line, the apoptotic effects of mTOR inhibitors in vivo also appear to be AKT-dependent. The mechanism of this regulation and the role of AKT in apoptosis are under investigation.
In summary, our data demonstrate that AKT regulates the sensitivity of MM cells to mTOR inhibitor-induced angiogenesis and VEGF expression. This may be clinically relevant because AKT hyperactivity is a frequent occurrence in myeloma (Hsu et al., 2001) and heightened AKT activity confers resistance to a variety of other anticancer therapies. Thus, mTOR inhibitors may have considerable potential in 'high-AKT' cases of MM. Furthermore, our results suggest that assessment of pretreatment AKT activity and monitoring the effect on VEGF expression may be predictive in clinical trials.
Materials and methods

Myeloma cell lines and transfection
The constitutively activated myristoylated-AKT (AKT) or empty vector (EV) cDNA expression vectors were purchased from Upstate (Charlottesville, VA, USA). Transfection of U266 cells with activated AKT or empty EV control was accomplished by electroporation (230 V for 25 ms) (Frost et al., 2004) . Stable transfections were selected in neomycin (350 mg/ml) and successful transfection was determined by Western blotting with antibodies specific for total and phosphorylated AKT (Ser473).
Reagents
Rapamycin was purchased from Calbiochem (San Diego, CA, USA). The CCI-779 was provided by Wyeth-Ayerst (Pearl River, NY, USA). Enzyme-linked immunosorbent assay (ELISA) kits specific for human VEGF and IL-8 were purchased from R&D Systems (Minneapolis, MN, USA).
Plasmids and generation of RNA transcripts
The plasmids pR-F, pR-VEGF-F (Lang et al., 2002) , pSP65-R-F and pSP65-R-VEGF-F were kind gifts from Dr Greg Goodall (University of Adelaide, Australia) (Bert et al., 2006) . Capped transcripts were synthesized using the mMESSAGE mMACHINE SP6 kit (Ambion, Austin, TX, USA) by 40 U SP6 RNA polymerase in the presence of 1 mM nucleosidetriphosphates, 10 mM dithiothrietol, 50 U RNasin, 5 mg of linearized plasmid template for 2 h at 371C, and DNA was removed by digestion for 15 min with RQ1 DNaseI (Promega, Madison, WI, USA). All RNAs were purified using Qiagen RNeasy mini kits to remove unincorporated nucleotides and cap analog. RNA quality was determined on a denaturing formaldehyde agarose gel.
Animals
Four-six-week-old male NOD/SCID mice were obtained from Jackson Laboratories (Bar Harbor, ME, USA). All animal studies were conducted in accordance with protocols approved by the Animal Research Committee of the West Los Angeles Veterans Administration Medical Center.
Xenograft model
We used the murine myeloma xenograft model of LeBlanc et al. (2002) with minor modifications (Frost et al., 2004) . The cell lines were mixed with matrigel and were then injected subcutaneously into the left flank (200 ml/mouse containing 3 Â 10 7 U266 cells) of the mice. Tumor growth was monitored daily, and mice were randomized into drug-treated or control groups (8-14 mice/group) when the tumor volume reached approximately 200-400 mm 3 . The CCI-779 drug solution (200 ml) was administered intraperitoneally daily Â 5, followed by 2 days of no drug and then five additional daily injections (total of 10 injections) (Neshat et al., 2001 ). Mice were routinely killed when tumors reached >2000 mm 3 in volume.
Immunohistochemistry At day þ 13 (24 h after last injection), some mice were killed with CO 2 and the tumor mass was excised. The tumor was bisected using a razor blade: one half of the tumor was immediately placed in 10% buffered formaldehyde overnight, and the other half was frozen for protein extraction. Formaldehyde fixed tumors were embedded in paraffin and cut into 5 mm-thick serial sections using standard histological procedures. Immunohistochemical staining with anti-mouse CD-34 antibody was conducted using standardized automated methods (Sugawara et al., 2002) . The MVD was determined by assaying the area of CD34 staining using the MetaMorph software (see below) from 10 randomly selected fields at Â 20 magnification. Images for publication were prepared using Adobe Photoshop computer software.
Morphometric analysis
Analysis of MVD was performed on tissue sections with a Nikon Microphot-SA microscope (Melville, NY, USA) equipped with plan-apochromat lenses ( Â 20 and Â 40). A Diagnostic Technologies digital camera, model SPOT-RT was used to capture images with a resolution of 1520 Â 1080 pixels. MetaMorph software (version 6.1) (Universal Imaging Corporation, West Chester, PA, USA) was used to measure percent area of CD34-stained tumor sections.
Polysome analysis U266 isogenic cells (4 Â 10 6 cells) were lysed in ice-cold lysis buffer supplemented with 100 mg/ml cycloheximide at 41C . Following removal of nuclei and mitochondria, supernatants were layered onto 15-50% sucrose gradients and spun at 38 000 r.p.m. for 2 h at 41C in a SW-40 rotor (Beckman Instruments, Fullerton, CA, USA). Eleven 1 ml fractions were collected using an ISCO Density Gradient Fractionator at a flow rate of 3 ml/min. The polysome profile of the gradient was determined by UV absorbance at 254 nm. The RNA from individual fractions was extracted using phenol/chloroform and precipitated in EtOH.
Northern blots analysis
Total RNA was isolated with the RNeasy Mini Kit (Qiagen, Valencia, CA, USA). Denatured RNA was separated using a 1% agarose gel containing 440 mM formyldehyde, transferred to positively charged membranes (Amersham Bioscience, Buckinghamshire, UK) crosslinked by UV irradiation and hybridized at 651C in 1 M NaCl, 10% dextran sulfate, 1% sodium dodecyl sulfate and 0.01% salmon sperm DNA. Radioactive probes were generated using the Ambion MaxiScript kit (Ambion, Austin TX, USA).
Dicistronic reporter assay
Isogenic U266 cells (1.5 Â 10 7 cells) were transfected with 500 ng RNA by electroporation (230 V for 25 ms). The cells were then incubated with or without 100 nM rapamycin for 18 h, washed twice in phosphate-buffered saline and lysed in passive lysis buffer (Promega). The Firefly luciferase and Renilla luciferase activities were measured in the lysate using the Dual-Luciferase Reporter Assay System (Promega). Transfection efficiency was measured by b-galactosidase activity using a b-Galactosidase enzyme Assay System (Promega).
Statistics
Student's t-test was used to determine significance of differences between groups.
